Mirtazapin - Wikiwand

Mirtazapin (Remeron, Avanza, Zispin) je noradrenergički i specifični serotonergički antidepresiv (NaSSA) koji je razvila kompanija u Sjedinjenim Državama 1990. godine. On se prvenstveno koristi za lečenje depresije. On isto takao nalazi primenu kao anksiolitik, hipnotik, antiemetik i stimulant apetita. On je strukturno sličan sa mianserinom, i klasifikuje se kao tetraciklični antidepresant (TeCA).

Кратке чињенице ime, Klinički podaci ...


ime


(±)-2-metil-1,2,3,4,10,14b-heksahidropirazino[2,1-a]pirido[2,3-c][2]benzazepin
Klinički podaci
Prodajno ime	Remeron, Avanza, Zispin
	Monografija

Kategorija trudnoće	C
Način primene	Oralno
Pravni status
Pravni status
Farmakokinetički podaci
Bioraspoloživost	50%^[1]
Vezivanje proteina	85%^[1]
Metabolizam	Hepatički (, i )^[1]^[2]
Poluvreme eliminacije	20–40 sata^[1]
Izlučivanje	Urin (75%)^[1] Izmet (15%)^[1]

Identifikatori
	61337-67-5^Y
kod	()
	4205
	^Y
	4060^Y
	^Y
	^Y
	:6950^Y
	654^Y
Sinonimi	6-Azamianserin, Org 3770
Hemijski podaci
Formula	₁₇₁₉₃
Molarna masa	265,35

^Y ^Y

Fizički podaci
Gustina	1,22 ³
Tačka topljenja
Tačka ključanja
Rastvorljivost u vodi	Rastvoran u metanolu i hloroformu (20 °)

Затвори

Medicinska upotreba

Mirtazapin se prvenstveno koristi za tretiranje kliničke depresije i drugih poremećaja raspoloženja.^[3]^[4]

On isto tako može da bude koristan u tretiranju sledećih oboljenja, mada nije odobren za te primene:

Generalizovani anksiozni poremećaj^[2]^[5]
Socijalna fobija^[6]^[7]
Opsesivno-kompulzivni poremećaj^[6]^[8]
Panični poremećaj^[6]^[9]^[10]
Posttraumatski stresni poremećaj^[6]
Anoreksija^[11]
Insomnija^[12]^[13]
Mučnina/povraćanje^[14]^[15]^[16]
Umanjeni apetit/nedovoljna telesna težina^[17]^[18]^[19]
Svrabež^[20]^[21]
Glavobolje i migrena^[15]^[22]^[23]

Reference

[1]
Timmer CJ, Sitsen JM, Delbressine LP (2000). „Clinical pharmacokinetics of mirtazapine”. Clinical Pharmacokinetics. 38 (6): 461—74. PMID 10885584. doi:10.2165/00003088-200038060-00001.^{[мртва веза]}
[2]
Anttila SA, Leinonen EV (2001). „A review of the pharmacological and clinical profile of mirtazapine”. CNS Drug Reviews. 7 (3): 249—64. PMID 11607047. doi:10.1111/j.1527-3458.2001.tb00198.x.
[3]
Gorman JM (1999). „Mirtazapine: clinical overview”. J Clin Psychiatry. 60 Suppl 17: 9—13; discussion 46—8. PMID 10446735.
[4]
Benjamin S, Doraiswamy PM (2011). „Review of the use of mirtazapine in the treatment of depression”. Expert Opinion on Pharmacotherapy. 12 (10): 1623—32. PMID 21644844. doi:10.1517/14656566.2011.585459.
[5]
Goodnick PJ, Puig A, DeVane CL, Freund BV (1999). „Mirtazapine in major depression with comorbid generalized anxiety disorder”. J Clin Psychiatry. 60 (7): 446—8. PMID 10453798. doi:10.4088/JCP.v60n0705.
[6]
Croom KF, Perry CM, Plosker GL (2009). „Mirtazapine: a review of its use in major depression and other psychiatric disorders”. CNS Drugs. 23 (5): 427—52. PMID 19453203. doi:10.2165/00023210-200923050-00006. Архивирано из оригинала 09. 02. 2013. г. Приступљено 18. 08. 2012.
[7]
Muehlbacher M; Nickel MK; Nickel C; . (2005). „Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study”. Journal of Clinical Psychopharmacology. 25 (6): 580—3. PMID 16282842. doi:10.1097/01.jcp.0000186871.04984.8d. Архивирано из оригинала 27. 11. 2015. г. Приступљено 18. 08. 2012.
[8]
Koran LM, Quirk T, Lorberbaum JP, Elliott M (2001). „Mirtazapine treatment of obsessive-compulsive disorder”. J Clin Psychopharmacol. 21 (5): 537—9. PMID 11593084. doi:10.1097/00004714-200110000-00016.
[9]
Carpenter LL, Leon Z, Yasmin S, Price LH (1999). „Clinical experience with mirtazapine in the treatment of panic disorder”. Ann Clin Psychiatry. 11 (2): 81—6. PMID 10440525. doi:10.3109/10401239909147053.
[10]
Carli V, Sarchiapone M, Camardese G, Romano L, DeRisio S (2002). „Mirtazapine in the treatment of panic disorder”. Arch. Gen. Psychiatry. 59 (7): 661—2. PMID 12090820. doi:10.1001/archpsyc.59.7.661.
[11]
Hrdlicka M, Beranova I, Zamecnikova R, Urbanek T (2008). „Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study”. European Child & Adolescent Psychiatry. 17 (3): 187—9. PMID 18357426. doi:10.1007/s00787-007-0670-8.
[12]
Hartmann PM (1999). „Mirtazapine: a newer antidepressant”. Am Fam Physician. 59 (1): 159—61. PMID 9917581.
[13]
Jindal RD (2009). „Insomnia in patients with depression: some pathophysiological and treatment considerations”. CNS Drugs. 23 (4): 309—29. PMID 19374460. Архивирано из оригинала 09. 02. 2013. г. Приступљено 18. 08. 2012.
[14]
Nutt DJ (2002). „Tolerability and safety aspects of mirtazapine”. Human Psychopharmacology. 17 Suppl 1: S37—41. PMID 12404669. doi:10.1002/hup.388.
[15]
Li TC, Shiah IS, Sun CJ, Tzang RF, Huang KC, Lee WK (2011). „Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature”. The Journal of ECT. 27 (2): 165—7. PMID 21602639. doi:10.1097/YCT.0b013e3181e63346. Архивирано из оригинала 09. 05. 2013. г. Приступљено 18. 08. 2012.
[16]
Kast RE, Foley KF (2007). „Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects”. Eur J Cancer Care (Engl). 16 (4): 351—4. PMID 17587360. doi:10.1111/j.1365-2354.2006.00760.x.
[17]
Landowski J (2002). „[Mirtazapine--an antidepressant]”. Psychiatria Polska (на језику: Polish). 36 (6 Suppl): 125—30. PMID 12647431.
[18]
Chinuck RS, Fortnum H, Baldwin DR (2007). „Appetite stimulants in cystic fibrosis: a systematic review”. Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association. 20 (6): 526—37. PMID 18001374. doi:10.1111/j.1365-277X.2007.00824.x.
[19]
Davis MP, Khawam E, Pozuelo L, Lagman R (2002). „Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project”. Expert Review of Anticancer Therapy. 2 (4): 365—76. PMID 12647979. doi:10.1586/14737140.2.4.365.
[20]
Twycross R; Greaves MW; Handwerker H; . (2003). „Itch: scratching more than the surface”. QJM : Monthly Journal of the Association of Physicians. 96 (1): 7—26. PMID 12509645. doi:10.1093/qjmed/hcg002.
[21]
Greaves MW (2005). „Itch in systemic disease: therapeutic options”. Dermatologic Therapy. 18 (4): 323—7. PMID 16297004. doi:10.1111/j.1529-8019.2005.00036.x.
[22]
Colombo B, Annovazzi PO, Comi G (2004). „Therapy of primary headaches: the role of antidepressants”. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 25 Suppl 3: S171—5. PMID 15549531. doi:10.1007/s10072-004-0280-x.
[23]
Tajti J, Almási J (2006). „[Effects of mirtazapine in patients with chronic tension-type headache. Literature review]”. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakológiai Egyesület Lapja = Official Journal of the Hungarian Association of Psychopharmacology (на језику: Hungarian). 8 (2): 67—72. PMID 17073214.

Literatura

Stimmel GL, Dopheide JA, Stahl SM (1997). „Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects”. Pharmacotherapy. 17 (1): 10—21. PMID 9017762.
Anttila SA, Leinonen EV (2001). „A review of the pharmacological and clinical profile of mirtazapine”. CNS Drug Rev. 7 (3): 249—64. PMID 11607047. doi:10.1111/j.1527-3458.2001.tb00198.x.

Spoljašnje veze

Wikiwand - on

Seamless Wikipedia browsing. On steroids.



ime
(±)-2-metil-1,2,3,4,10,14b-heksahidropirazino[2,1-a]pirido[2,3-c][2]benzazepin
Klinički podaci
Prodajno ime	Remeron, Avanza, Zispin
	Monografija

Kategorija trudnoće	C
Način primene	Oralno
Pravni status
Pravni status
Farmakokinetički podaci
Bioraspoloživost	50%^[1]
Vezivanje proteina	85%^[1]
Metabolizam	Hepatički (, i )^[1]^[2]
Poluvreme eliminacije	20–40 sata^[1]
Izlučivanje	Urin (75%)^[1] Izmet (15%)^[1]

Identifikatori
	61337-67-5^Y
kod	()
	4205
	^Y
	4060^Y
	^Y
	^Y
	:6950^Y
	654^Y
Sinonimi	6-Azamianserin, Org 3770
Hemijski podaci
Formula	₁₇₁₉₃
Molarna masa	265,35

^Y ^Y

Fizički podaci
Gustina	1,22 ³
Tačka topljenja
Tačka ključanja
Rastvorljivost u vodi	Rastvoran u metanolu i hloroformu (20 °)

[1]
Timmer CJ, Sitsen JM, Delbressine LP (2000). „Clinical pharmacokinetics of mirtazapine”. Clinical Pharmacokinetics. 38 (6): 461—74. PMID 10885584. doi:10.2165/00003088-200038060-00001.^{[мртва веза]}
[2]
Anttila SA, Leinonen EV (2001). „A review of the pharmacological and clinical profile of mirtazapine”. CNS Drug Reviews. 7 (3): 249—64. PMID 11607047. doi:10.1111/j.1527-3458.2001.tb00198.x.
[3]
Gorman JM (1999). „Mirtazapine: clinical overview”. J Clin Psychiatry. 60 Suppl 17: 9—13; discussion 46—8. PMID 10446735.
[4]
Benjamin S, Doraiswamy PM (2011). „Review of the use of mirtazapine in the treatment of depression”. Expert Opinion on Pharmacotherapy. 12 (10): 1623—32. PMID 21644844. doi:10.1517/14656566.2011.585459.
[5]
Goodnick PJ, Puig A, DeVane CL, Freund BV (1999). „Mirtazapine in major depression with comorbid generalized anxiety disorder”. J Clin Psychiatry. 60 (7): 446—8. PMID 10453798. doi:10.4088/JCP.v60n0705.
[6]
Croom KF, Perry CM, Plosker GL (2009). „Mirtazapine: a review of its use in major depression and other psychiatric disorders”. CNS Drugs. 23 (5): 427—52. PMID 19453203. doi:10.2165/00023210-200923050-00006. Архивирано из оригинала 09. 02. 2013. г. Приступљено 18. 08. 2012.
[7]
Muehlbacher M; Nickel MK; Nickel C; . (2005). „Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study”. Journal of Clinical Psychopharmacology. 25 (6): 580—3. PMID 16282842. doi:10.1097/01.jcp.0000186871.04984.8d. Архивирано из оригинала 27. 11. 2015. г. Приступљено 18. 08. 2012.
[8]
Koran LM, Quirk T, Lorberbaum JP, Elliott M (2001). „Mirtazapine treatment of obsessive-compulsive disorder”. J Clin Psychopharmacol. 21 (5): 537—9. PMID 11593084. doi:10.1097/00004714-200110000-00016.
[9]
Carpenter LL, Leon Z, Yasmin S, Price LH (1999). „Clinical experience with mirtazapine in the treatment of panic disorder”. Ann Clin Psychiatry. 11 (2): 81—6. PMID 10440525. doi:10.3109/10401239909147053.
[10]
Carli V, Sarchiapone M, Camardese G, Romano L, DeRisio S (2002). „Mirtazapine in the treatment of panic disorder”. Arch. Gen. Psychiatry. 59 (7): 661—2. PMID 12090820. doi:10.1001/archpsyc.59.7.661.
[11]
Hrdlicka M, Beranova I, Zamecnikova R, Urbanek T (2008). „Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study”. European Child & Adolescent Psychiatry. 17 (3): 187—9. PMID 18357426. doi:10.1007/s00787-007-0670-8.
[12]
Hartmann PM (1999). „Mirtazapine: a newer antidepressant”. Am Fam Physician. 59 (1): 159—61. PMID 9917581.
[13]
Jindal RD (2009). „Insomnia in patients with depression: some pathophysiological and treatment considerations”. CNS Drugs. 23 (4): 309—29. PMID 19374460. Архивирано из оригинала 09. 02. 2013. г. Приступљено 18. 08. 2012.
[14]
Nutt DJ (2002). „Tolerability and safety aspects of mirtazapine”. Human Psychopharmacology. 17 Suppl 1: S37—41. PMID 12404669. doi:10.1002/hup.388.
[15]
Li TC, Shiah IS, Sun CJ, Tzang RF, Huang KC, Lee WK (2011). „Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature”. The Journal of ECT. 27 (2): 165—7. PMID 21602639. doi:10.1097/YCT.0b013e3181e63346. Архивирано из оригинала 09. 05. 2013. г. Приступљено 18. 08. 2012.
[16]
Kast RE, Foley KF (2007). „Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects”. Eur J Cancer Care (Engl). 16 (4): 351—4. PMID 17587360. doi:10.1111/j.1365-2354.2006.00760.x.
[17]
Landowski J (2002). „[Mirtazapine--an antidepressant]”. Psychiatria Polska (на језику: Polish). 36 (6 Suppl): 125—30. PMID 12647431.
[18]
Chinuck RS, Fortnum H, Baldwin DR (2007). „Appetite stimulants in cystic fibrosis: a systematic review”. Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association. 20 (6): 526—37. PMID 18001374. doi:10.1111/j.1365-277X.2007.00824.x.
[19]
Davis MP, Khawam E, Pozuelo L, Lagman R (2002). „Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project”. Expert Review of Anticancer Therapy. 2 (4): 365—76. PMID 12647979. doi:10.1586/14737140.2.4.365.
[20]
Twycross R; Greaves MW; Handwerker H; . (2003). „Itch: scratching more than the surface”. QJM : Monthly Journal of the Association of Physicians. 96 (1): 7—26. PMID 12509645. doi:10.1093/qjmed/hcg002.
[21]
Greaves MW (2005). „Itch in systemic disease: therapeutic options”. Dermatologic Therapy. 18 (4): 323—7. PMID 16297004. doi:10.1111/j.1529-8019.2005.00036.x.
[22]
Colombo B, Annovazzi PO, Comi G (2004). „Therapy of primary headaches: the role of antidepressants”. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 25 Suppl 3: S171—5. PMID 15549531. doi:10.1007/s10072-004-0280-x.
[23]
Tajti J, Almási J (2006). „[Effects of mirtazapine in patients with chronic tension-type headache. Literature review]”. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakológiai Egyesület Lapja = Official Journal of the Hungarian Association of Psychopharmacology (на језику: Hungarian). 8 (2): 67—72. PMID 17073214.